Efficacy of amiodarone in preventing reperfusion ventricular fibrillation in patients undergoing cardiac surgery
10.3760/cma.j.cn112434-20200313-00126
- VernacularTitle:胺碘酮预防心脏手术再灌注心室颤动的疗效
- Author:
Bin XIONG
;
Limin HE
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2021;37(3):168-172
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of amiodarone in preventing reperfusion ventricular fibrillation (RVF) in patients undergoing cardiac surgery.Methods:This study searched the databases of CNKI, Wanfang, Weipu, Cochrane, Embase, Web of Knowledge and PubMed, and searched the related research of amiodarone to prevent RVF in cardiac surgery patients, the time was until December 2019. Meta analysis was performed using Revman 5.3 software according to established standards.Results:The study included six studies (incorporating 514 patients). According to different intervention methods, 514 patients were divided into three groups, 196 in the amiodarone group, 153 in the lidocaine group, and 165 in the placebo group. The incidence of RVF was significantly lower in the amiodarone group than in the control group ( RR: 0.64, 95% CI: 0.47-0.86, P=0.003, I2=49%), but there was no significant difference between the amiodarone group and the lidocaine group( RR: 1.03, 95% CI: 0.48-2.22, P=0.94, I2=74%). Compared with the control group, amiodarone reduced the defibrillation frequency of RVF, but the difference was not statistically significant ( RR: 0.90, 95% CI: 0.68-1.20, P=0.48, I2=0). There was no difference in the number of defibrillation of RVF between the lidocaine group and the amiodarone groups ( RR: 1.50, 95% CI: 0.90-2.52, P=0.12, I2=38%). Conclusion:Compared with the control group, amiodarone can significantly reduce the incidence of RVF in patients undergoing cardiac surgery.
